Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat).
Lipoprotein lipase (LPL) was rapidly inactivated by low concentrations of the active-site inhibitor tetrahydrolipstatin (THL). The presence of amphiphils (e.g. long-chain fatty acids) or of lipid/water interfaces (lipid emulsions) was required for inhibition to occur. Apolipoprotein CII increased the maximal inactivation rate constant by 1.8-fold in the presence of an emulsion of long-chain triacylglycerols, but had no effect in the presence of an emulsion of tributyrylglycerol. The fully inhibited enzyme had a ratio of THL/LPL of nearly 2, indicating that both subunits of the LPL homo-dimer bound THL. The THL-LPL complex was stable below pH 7.5. At higher pH reactivation occurred indicating that THL was slowly turned over by the enzyme. The apparent reactivation rate constant was increased about threefold by the presence of lipid/water interfaces. Sucrose density gradient centrifugation revealed that THL induces tetramerisation of LPL. This aggregation was reversible on reactivation of the inhibited enzyme. Binding to heparin was not affected by THL. In contrast, binding to lipid droplets and to lipoproteins was increased, indicating exposure of hydrophobic regions in the inhibited LPL. It is suggested that THL induces local conformational changes in LPL, which may involve opening of the putative surface lid structure which covers the active-site.
Lookene
A
A
Department of Medical Biochemistry and Biophysics, University of Umeå, Sweden.
Skottova
N
N
Olivecrona
G
G
D000818:Animals; D053304:Apolipoprotein C-II; D001056:Apolipoproteins C / Q000494:pharmacology; D001665:Binding Sites; D002846:Chromatography, Affinity; D002914:Chylomicrons / Q000302:isolation & purification / Q000378:metabolism; D003840:Deoxycholic Acid / Q000494:pharmacology; D004789:Enzyme Activation; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology; D007700:Kinetics; D007783:Lactones / Q000378:metabolism* / Q000494:pharmacology; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors / Q000097:blood* / Q000302:isolation & purification; D008196:Lymph / Q000378:metabolism; D046911:Macromolecular Substances; D000077403:Orlistat; D011485:Protein Binding; D051381:Rats; D014215:Triacetin / Q000494:pharmacology; D014280:Triglycerides / Q000494:pharmacology; D014304:Triolein / Q000494:pharmacology
D053304:Apolipoprotein C-II; D001056:Apolipoproteins C; D002914:Chylomicrons; D005217:Fat Emulsions, Intravenous; D007783:Lactones; D046911:Macromolecular Substances; D014280:Triglycerides; D003840:Deoxycholic Acid; D014304:Triolein; D000077403:Orlistat; D008071:Lipoprotein Lipase; C005830:tributyrin; D014215:Triacetin